
    
      Open label study with 20 participants, with block dose escalation (3 patients each at 2, 5,
      10, 15, 20 part-per-million, 5 additional patients at 20 ppm or next highest safe dose). The
      primary outcomes are safety during 4 hours of inhalation (including measures of methemoglobin
      and ethanol byproducts) and 7 day adverse events
    
  